Valuation: GENFIT

Market Cap 47Cr 52Cr 44Cr 39Cr 74Cr 5.05TCr 75Cr 523.27Cr 203.32Cr 2.58TCr 196.61Cr 192.38Cr 8.28TCr P/E 2026 *
84.8x
P/E 2027 * 98.7x
Enterprise Value 44Cr 50Cr 42Cr 38Cr 71Cr 4.82TCr 72Cr 499.07Cr 193.92Cr 2.46TCr 187.52Cr 183.49Cr 7.9TCr EV / Sales 2026 *
4.09x
EV / Sales 2027 * 3.06x
Free-Float
86.89%
Yield 2026 *
-
Yield 2027 * -
1 day-3.26%
3 months+46.51%
6 months+51.01%
Current year+162.50%
Current year 7.26
Extreme 7.26
16.5
1 year 4.14
Extreme 4.14
16.5
3 years 2.95
Extreme 2.95
16.5
5 years 2.95
Extreme 2.95
16.5
10 years 0
Extreme 0
36.86
Manager TitleAgeSince
Chief Executive Officer 58 16/09/2019
Director of Finance/CFO 52 22/04/2021
Chief Tech/Sci/R&D Officer - 27/11/2025
Director TitleAgeSince
Chairman 70 16/06/2017
Director/Board Member 54 15/09/1999
Director/Board Member 58 16/06/2017
Change 5-day change 1-year change 3-year change Capi.($)
-3.26%-.--% - - 52Cr
+4.16%+3.42%+49.37%+94.17% 7.43TCr
+2.76%-1.16%+23.05%+83.03% 5.7TCr
+0.24%-1.37%+4.08%+37.22% 4.83TCr
-3.76%-0.93%+327.90%+691.25% 4.45TCr
-2.30%-4.06%+25.82%+31.42% 4.38TCr
+0.31%-1.15%+5.50%+112.56% 4.11TCr
-0.11%+2.30%+9.19%+58.68% 3.11TCr
+4.51%+8.43%+37.27%+34.97% 2.9TCr
-1.96%-3.38%-9.25%-12.85% 2.45TCr
Average +0.06%-0.20%+52.55%+125.61% 4.37TCr
Weighted average by Cap. +0.76%-0.50%+56.58%+134.21%

Financials

2026 *2027 *
Net sales 11Cr 12Cr 10Cr 9.2Cr 17Cr 1.18TCr 17Cr 122.03Cr 47Cr 601.12Cr 46Cr 45Cr 1.93TCr 13Cr 15Cr 12Cr 11Cr 21Cr 1.41TCr 21Cr 146.06Cr 57Cr 719.46Cr 55Cr 54Cr 2.31TCr
Net income 1.03Cr 1.16Cr 96.39L 87.36L 1.65Cr 111.78Cr 1.66Cr 12Cr 4.5Cr 57Cr 4.35Cr 4.26Cr 183.36Cr 1.04Cr 1.17Cr 97.02L 87.93L 1.66Cr 112.5Cr 1.67Cr 12Cr 4.53Cr 57Cr 4.38Cr 4.29Cr 184.55Cr
Net Debt -2.15Cr -2.42Cr -2.01Cr -1.83Cr -3.44Cr -233.54Cr -3.47Cr -24Cr -9.4Cr -119.21Cr -9.09Cr -8.9Cr -383.08Cr -6.76Cr -7.61Cr -6.32Cr -5.73Cr -11Cr -733.18Cr -11Cr -76Cr -30Cr -374.25Cr -29Cr -28Cr -1.2TCr
Projected Income Statement - Annual - GENFIT
Logo GENFIT
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades. The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
Employees
161
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - GENFIT
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
9.300EUR
Average target price
17.48EUR
Spread / Average Target
+87.96%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - GENFIT